PMDA drug package insert
キイジェクト配合皮下注395mg
PMDA Prescription drug · MSD株式会社 · package insert Sep 16, 2026
Key facts
| Brand names | キイジェクト配合皮下注395mg, キイジェクト配合皮下注790mg |
|---|---|
| Nonproprietary names | ペムブロリズマブ（遺伝子組換え）・ベラヒアルロニダーゼ アルファ（遺伝子組換え） |
| Companies | 製造販売元／MSD株式会社 |
| Product type | Prescription drug |
| Therapeutic category | ─抗悪性腫瘍剤─; ヒト化抗ヒトPD-1モノクローナル抗体・ヒアルロン酸分解酵素配合剤 |
| Therapeutic category codes | 874291 |
| YJ codes | 42915A4A1025, 42915A4A2021 |
| Approval numbers | 30800AMX00328000, 30800AMX00329000 |
| Package insert edition | 第1版 |
| Package insert date | Sep 16, 2026 |
| PMDA document key | 170050_42915A4A1025_1 |
| PMDA company code | 170050 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: